As the predominant histologic subtype of non-small cell lung cancer (NSCLC), lung adenocarcinoma demonstrates the highest incidence of brain metastasis (BM), with EGFR-positive patients exhibiting particularly predisposed to developing BM within 24 months of initial diagnosis [1,2]. The clinical prognosis for BM remains dismal, and median overall survival (OS) durations is between 3 and 14.8 months across major clinical trials [3–5]. Notably, first-line EGFR tyrosine kinase inhibitor (TKI) thera…